ITEM Establishes Competence Centre for Pharma Innovation

The Institute of Technology Management (ITEM) has announced the formal establishment of the Competence Centre for Pharma Innovation (CPI). A key objective is to enhance the group's visibility to the outside world, building upon a strong foundation of research conducted over the past ten years.

This research includes 25 papers published in leading industry journals such as Nature Reviews Drug Discovery, Drug Discovery Today, and the Journal of Translational Medicine, with features in Forbes magazine. The CPI will continue its focus on "Pharma R&D Productivity" and its various facets, aiming to conduct comprehensive analyses and deliver innovative, practice-relevant insights.

The CPI's mission encompasses establishing a globally recognized research group specializing in pharmaceutical R&D management, raising awareness of industry challenges, and providing pharma executives with actionable knowledge. Key fields of observation include Pharma R&D strategies, pharmaceutical innovation, R&D business models, emerging technologies, and drug approval processes.

Initially driven by a core network of four people, the broader team includes Prof. Dr. Oliver Gassmann, Prof. Dr. Alexander Schuhmacher, Prof. Dr. Dominik Hartl (GraniteBio), and Prof. Dr. Markus Hinder (Novartis). Their work has already garnered significant attention from industry executives, consultants, investors, and academic researchers. The CPI is committed to continuing its publication activities in leading scientific journals relevant to the pharmaceutical industry.